Value
7.9/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 9.4 |
| EV/EBITDA | 7.2 |
| Fwd P/E | 9.8 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 6.5x
- ▸PEG: 0.01
- ▸Attractively valued
VTRS · Why this verdict
Why Viatris (VTRS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Viatris is a specialty and generic drug manufacturer with a perfect 4-quarter earnings beat streak, a forward P/E of 6.1x, and a PEG ratio of 0.01 — deeply cheap on valuation — but the business is flagged as below quality threshold with operating margins of only 2.8%, negative free cash flow, and a dividend that is flagged as a yield trap, creating a classic value-trap setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Operating margins have compressed to 2.8% — a level flagged as a value trap signal — with negative free cash flow creating a second value-trap indicator; both conditions together mean the apparent low multiple at 6.1x forward P/E may reflect genuine fundamental impairment rather than a discount. Bear case | Operating margins should recover above 5% within 12 months as cost reduction initiatives take effect, demonstrating that the margin compression is cyclical rather than structural. | →Stable |
| CounterGeneric drug companies face structural pricing pressure from pharmacy benefit managers and government pricing reform; the 2.8% operating margin may represent the new normal rather than a trough, making the value trap designation accurate. | ||
Viatris has beaten earnings estimates in all 4 of the last 4 quarters with an average positive surprise of 11.25%, including beats of 17.54%, 7.39%, 8.52%, and 11.55% — consistent execution above analyst expectations despite the quality concerns flagged at the business level. Catalyst breakdown | The beat streak should continue with positive EPS surprises in at least 3 of the next 4 quarters, and earnings per share should remain above $0.55 per quarter to sustain the current low multiple. | →Stable |
| CounterConsistent beats in a generic drug company with 2.8% operating margins may reflect analysts that have already priced in structural deterioration; the beats are modest in absolute terms (averaging $0.07 per share outperformance) and do not address the margin compression. | ||
Free cash flow is negative, meaning the company is consuming cash despite reporting positive GAAP earnings — a condition where accounting income overstates real economic profit, and the business cannot fund growth, debt repayment, or dividends from internal cash generation. Warnings | Free cash flow should turn positive within 2 quarters, and the free cash flow yield should rise above 5% within 12 months, confirming the business has returned to positive cash generation. | →Stable |
| CounterNegative free cash flow in a pharmaceutical company can be driven by one-time legal settlements, working capital timing, or restructuring charges rather than ongoing operational deterioration, and may resolve within 1-2 quarters. | ||
The dividend is flagged as a yield trap with an unsafe payout, and the payout is estimated at 60% of earnings in the catalyst score — but with negative free cash flow, the dividend is being funded by borrowing or asset liquidation rather than real earnings. Catalyst breakdown | Free cash flow should recover to above 100% of the dividend per share within 12 months to remove the yield trap designation and demonstrate the payout is genuinely sustainable. | →Stable |
| CounterManagement teams at pharmaceutical companies rarely cut dividends in the short term even under cash pressure, as dividend cuts signal capitulation; Viatris may sustain the dividend through the trough even if it is technically unsustainable for 1-2 quarters. | ||
Operating margins have compressed to 2.8% — a level flagged as a value trap signal — with negative free cash flow creating a second value-trap indicator; both conditions together mean the apparent low multiple at 6.1x forward P/E may reflect genuine fundamental impairment rather than a discount.
→StableBear case
- Expectation
- Operating margins should recover above 5% within 12 months as cost reduction initiatives take effect, demonstrating that the margin compression is cyclical rather than structural.
CounterGeneric drug companies face structural pricing pressure from pharmacy benefit managers and government pricing reform; the 2.8% operating margin may represent the new normal rather than a trough, making the value trap designation accurate.
Viatris has beaten earnings estimates in all 4 of the last 4 quarters with an average positive surprise of 11.25%, including beats of 17.54%, 7.39%, 8.52%, and 11.55% — consistent execution above analyst expectations despite the quality concerns flagged at the business level.
→StableCatalyst breakdown
- Expectation
- The beat streak should continue with positive EPS surprises in at least 3 of the next 4 quarters, and earnings per share should remain above $0.55 per quarter to sustain the current low multiple.
CounterConsistent beats in a generic drug company with 2.8% operating margins may reflect analysts that have already priced in structural deterioration; the beats are modest in absolute terms (averaging $0.07 per share outperformance) and do not address the margin compression.
Free cash flow is negative, meaning the company is consuming cash despite reporting positive GAAP earnings — a condition where accounting income overstates real economic profit, and the business cannot fund growth, debt repayment, or dividends from internal cash generation.
→StableWarnings
- Expectation
- Free cash flow should turn positive within 2 quarters, and the free cash flow yield should rise above 5% within 12 months, confirming the business has returned to positive cash generation.
CounterNegative free cash flow in a pharmaceutical company can be driven by one-time legal settlements, working capital timing, or restructuring charges rather than ongoing operational deterioration, and may resolve within 1-2 quarters.
The dividend is flagged as a yield trap with an unsafe payout, and the payout is estimated at 60% of earnings in the catalyst score — but with negative free cash flow, the dividend is being funded by borrowing or asset liquidation rather than real earnings.
→StableCatalyst breakdown
- Expectation
- Free cash flow should recover to above 100% of the dividend per share within 12 months to remove the yield trap designation and demonstrate the payout is genuinely sustainable.
CounterManagement teams at pharmaceutical companies rarely cut dividends in the short term even under cash pressure, as dividend cuts signal capitulation; Viatris may sustain the dividend through the trough even if it is technically unsustainable for 1-2 quarters.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 1.5 |
| Gross margin | 4.0 |
| Op margin | 2.7 |
| Net margin | 0.0 |
| Current ratio | 5.8 |
| Moat | 4.4 |
| Piotroski F | 8.9 |
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 8/9
Growth
4.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 4.5 |
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 8.4 |
| OBV | 6.5 |
| MA position | 9.0 |
| Volume | 2.8 |
- ▸Overbought (RSI 72)
- ▸Above 200-day MA
Sentiment
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.8 |
| Price target | 5.2 |
| erm sentiment | 4.9 |
- ▸Light analyst coverage (8.0) — signal dampened
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Negligible insider selling — $809,784 (0.004% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.3 |
| quality rank | 3.6 |
| growth rank | 5.6 |
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 9.9 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.9 |
| days to cover | 5.7 |
| volatility | 5.3 |
| put call | 5.9 |
| implied vol | 4.6 |
| beta | 7.6 |
| debt equity | 5.0 |
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 8.1 |
| dividend safety | 4.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.2>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:16d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.88
Upside
-11.9%
Downside
13.5%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 16d with 4/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's -0.9=NEGATIVE outcome against Value at 7.9 and asymmetric R:R of -0.88.
The strongest dimensions are Value at 7.9, Insider at 7.3, and Catalyst at 6.4; the weakest are Technical at 3.4, Quality at 3.4, and Growth at 4.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.88 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Beat Streak Low Quality
Trip ifEPS surprise falls below 0% in at least 3 of the next 4 quarters.
- P2Value Trap Margin Compression
Trip ifOperating margin falls below 1.5%, more than 1.3 percentage points below the already-depressed current level of 2.8%, for 2 consecutive quarters.
- P3Negative Free Cash Flow
Trip ifFree cash flow remains negative for more than 3 consecutive quarters, indicating the cash consumption is not recovering.
- P4Dividend Yield Trap
Trip ifDividend is cut by more than 30% below the current level, confirming the yield trap has triggered.